Ocuphire Pharma Investor Presentation Deck

Ocuphire Pipeline Product Candidate APX3330 Oral Pill APX3330 Local Delivery APX2009 and APX2014 Local Delivery NyxolⓇ Eyedrops Ocuphire Indication Diabetic Retinopathy (DR) Retina Retina Reversal of Mydriasis (RM) Presbyopia (P) Dim Light or Night Vision Disturbances (DLD) Pre-clinical Phase 1 Phase 2 Phase 3 EOP2 Meeting Regulatory Approval Partnered with Viatris Upcoming Milestones I EOP2 Mtg Q4 2023 Select retinal drug delivery technology Select retinal drug delivery technology PDUFA Date Sep 28, 2023 VEGA-2 Phase 3 Topline Data Q4 2023 OLYNX-2 2nd Phase 3 trial (n=150+) 4

View entire presentation